ClinicalTrials.gg
Status unknownNCT02789475Updated Jun 3, 2016

DP-R212 Pharmacokinetic Study

A Phase 1 interventional study of Amlodipine and Rosuvastatin in Hypertension and Hyperlipidemias, sponsored by Alvogen Korea. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-03.

Sponsored by Alvogen Korea (part of Lotus Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
19 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Planned enrollment
159th of 186
38 · median 180
Started
2016
with 8 others
Phase 1
17 of 187
none open now
Registered
137th of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 159th largest by planned enrollment of the 186 interventional ones that give a count, is one of 9 that started in 2016, is one of 17 in phase 1, and was the 137th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

An open-label, multiple-dose study to evaluate the pharmacokinetic drug-drug interaction of amlodipine and rosuvastatin in healthy adult male subjects.

03

Conditions studied

  • Hypertension
  • Hyperlipidemias
04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-29
  • signed the form prior to the study participation

Exclusion criteria

Exclusion Criteria:

  • disease
  • Previously donate whole blood within 60 days or component blood within 14 days
  • Clinically significant allergic disease
  • Taken IP in other trial within 90 days
  • An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    amplodipine group

    Amlodipine for 8 days and Amlodipine+Rosuvastatin for 5 days

    Drug: Amlodipine · Drug: Rosuvastatin

  • Experimental
    rosuvastatin group

    Rosuvastatin for 5 days and Amlodipine+Rosuvastatin for 8 days

    Drug: Amlodipine · Drug: Rosuvastatin

Interventions

  • Amlodipine administration

  • DrugRosuvastatin

    Rosuvastatin administration

06

What researchers measure

Primary outcomes

  1. AUCτ,ss of Amlodipine and Rosuvastatin

    Time frame: 0,0.5,1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hr

  2. Cmax,ss of Amlodipine and Rosuvastatin

    Time frame: 0,0.5,1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hr

07

Study locations

1 of 1 sites recruiting
  • Inha university hospital
    Jung-gu, Incheon 400-711, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2016
First posted
Jun 3, 2016
Start
May 2016
Primary completionEst.
Jul 2016
CompletionEst.
Jul 2016
Last update
Jun 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02789475
Lead sponsor
Alvogen Korea
Responsible party
Sponsor
First posted
Jun 3, 2016
Start date
May 2016
Primary completion
Jul 2016 (estimated)
Completion
Jul 2016 (estimated)
Last update
Jun 3, 2016

Study contacts

Chul woo Kim, Ph.D.
Contact
cwkim1805@inha.ac.kr
82-92-890-1168
Chul woo Kim, Ph.D.
principal investigator · Inha University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion